
Cellectar Biosciences, Inc.
NASDAQ:CLRB
0.25 (USD) • At close May 8, 2025
Overzicht | Financiële gegevens
Bedrijfsnaam | Cellectar Biosciences, Inc. |
Symbool | CLRB |
Munteenheid | USD |
Prijs | 0.252 |
Beurswaarde | 11,589,095 |
Dividendpercentage | 0% |
52-weken bereik | 0.22 - 3.49 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. James V. Caruso |
Website | https://www.cellectar.com |
An error occurred while fetching data.
Over Cellectar Biosciences, Inc.
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)